Our m6A score can differentiate metastatic PCa from non-metastatic PCa, though highlighting its clinical utility though a large-scale clinical validation cohort is still required to compare with other biomarkers such as AR-V7 [52]. This evidence concerns the gene AR and posterior cortical atrophy.